share_log

Jiangsu Aoyang Health Industryltd's (SZSE:002172) Solid Earnings Are Supported By Other Strong Factors

Jiangsu Aoyang Health Industryltd's (SZSE:002172) Solid Earnings Are Supported By Other Strong Factors

江蘇奧洋健康產業有限公司(SZSE:002172)穩健業績受到其他強勁因素的支持
Simply Wall St ·  11/07 07:03

Jiangsu Aoyang Health Industry Co.ltd. (SZSE:002172) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details.

江蘇澳洋健康業報告稱(SZSE:002172)剛剛宣佈了健康的營業收入,但股價並未有太大波動。我們的分析表明,投資者可能錯過了一些有前景的細節。

big
SZSE:002172 Earnings and Revenue History November 6th 2024
SZSE:002172 營業收入和歷史數據 2024年11月6日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

For anyone who wants to understand Jiangsu Aoyang Health Industryltd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥12m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Jiangsu Aoyang Health Industryltd to produce a higher profit next year, all else being equal.

對於任何希望了解澳洋健康業超越法定數字的利潤的人,重要的是要注意,在過去的十二個月中,由於飛凡項目,法定利潤減少了1200萬人民幣。 雖然由於飛凡項目而產生的扣除在第一次出現時令人失望,但其中也有一絲曙光。 當我們分析全球大多數上市公司時,我們發現重要的飛凡項目通常不會再次出現。 而且,歸根結底,這正是會計術語所暗示的。 假設這些飛凡開支不再出現,我們因此預計澳洋健康業明年將產生更高的利潤,其他條件保持不變。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangsu Aoyang Health Industryltd.

注:我們始終建議投資者檢查資產負債表的實力。 點擊這裏查看我們對江蘇澳洋健康業資產負債表分析。

Our Take On Jiangsu Aoyang Health Industryltd's Profit Performance

我們對江蘇澳洋健康業的利潤表現看法

Because unusual items detracted from Jiangsu Aoyang Health Industryltd's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Jiangsu Aoyang Health Industryltd's statutory profit actually understates its earnings potential! And one can definitely find a positive in the fact that it made a profit this year, despite losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. While conducting our analysis, we found that Jiangsu Aoyang Health Industryltd has 1 warning sign and it would be unwise to ignore it.

由於一些不尋常的項目在過去一年中減少了江蘇澳洋健康的收入,可以說我們可以期待當前季度有改善的業績。根據這一觀察,我們認爲江蘇澳洋健康的法定利潤實際上低估了其盈利潛力!而事實上,今年實現盈利,儘管去年虧損,這本身就可以被視爲積極因素。當然,我們只是剛剛開始分析其收益,人們也可以考慮利潤率、預測增長、投資回報率等其他因素。因此,如果您想深入了解這支股票,考慮其面臨的任何風險至關重要。在進行分析時,我們發現江蘇澳洋健康有1個警告信號,忽視它是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Jiangsu Aoyang Health Industryltd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天我們聚焦在一個數據點上,以更好地了解江蘇澳洋健康的利潤性質。但如果您能夠專注於細枝末節,總會有更多值得發現的地方。一些人認爲高淨資產收益率是優質業務的好跡象。雖然您可能需要進行一些調查,但您可能會發現這個免費的高淨資產收益率公司收藏,或者這個持有內部持股的股票清單對您有所幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論